# Veradermics' VDPHL01 Meets All Endpoints

> Veradermics' lead hair loss treatment meets all study endpoints in Phase 3 trial.
- Title: Veradermics' VDPHL01 Meets All Endpoints · TokenPost
- Summary: Veradermics' lead hair loss treatment meets all study endpoints in Phase 3 trial. Veradermics' VDPHL01 met all primary and secondary endpoints in the…
- Keywords: veradermics, vdp hl01, phase 3, hair loss, pattern hair loss, androgenetic alopecia, placebo controlled, crypto, finance, Veradermics', VDPHL01, Meets
- Source: TokenPost — https://tokenpost.com/news/business/34839
- Published: 2026-10-19T14:44:14+00:00
- Read time: 1 min
- Topics: veradermics, vdp hl01, phase 3, hair loss, pattern hair loss, androgenetic alopecia, placebo controlled, crypto, finance
## Study Results
Veradermics' lead candidate VDPHL01 met all primary and secondary endpoints in the six-month placebo-controlled Part A of Phase 3 Study '304' for men with mild-to-moderate pattern hair loss.
## Trial Details
The six-month study enrolled 536 men with mild-to-moderate pattern hair loss, also known as androgenetic alopecia.
## Significance
This positive late-stage result applies to the six-month comparison with placebo, not the study's longer extension phase.
## Key takeaway

Veradermics' VDPHL01 met all primary and secondary endpoints in the six-month Phase 3 study for mild-to-moderate pattern hair loss.